The good Doc is getting a lot of responses pointin
Post# of 145248
He did not respond after his classical “why the low marketcap” not even on your -and others- explanation.
While he did respond to others.
Maybe he’s busy studying Cydy now and wants to give an opinionated response.
![](/images/icons/icon_smile.gif)
It is somewhat strange though that in a company analysis not all competing companies in phase 3 HIV trials are taken into account.
It’s not so hard to find out who are of have completed phase 3 trials.
Cydy is really unknown (or unwanted?).
I’ve added a comment to the SA article too. The more the merrier!
![](/images/icons/icon_smile.gif)
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)